© 2022 MJH Life Sciences and Modern Retina. All rights reserved.
© 2022 MJH Life Sciences™ and Modern Retina. All rights reserved.
January 27, 2022
A team of investigators are working on a simple test that may someday identify those who can stop therapy.
January 26, 2022
Across four studies, about half of eligible faricimab patients were able to go 4 months between treatments, and approximately three-quarters could be treated every 3 months or longer. Two papers published in The Lancet highlight one-year results.
The historic Eye Institute rings in 60 years of leadership in eye care research, education and clinical practice.
January 25, 2022
The meeting places a special emphasis on pharmacotherapies in the pipeline for the treatment of neovascular exudative diseases of the eye and how they will affect clinical practice and Medicare.
January 24, 2022
Approach shows potential as a promising second-line screening tool for patients with diabetes.
January 23, 2022
According to the company, biped.ai includes a comfortable and lightweight collar fitted with 3D cameras that continuously monitor a 170° field of view for the user detecting, tracking and predicting the trajectories of all surrounding elements a few seconds in advance.
January 22, 2022
Since joining the foundation in 2018, Menzo has been involved in the formation of the Retinal Degeneration Fund, the venture arm of Foundation Fighting Blindness.
January 21, 2022
The difference between retina’s biological age and person’s real age linked to heightened death risk, with a team of Australian investigators finding that evidence suggests the microvasculature in the retina may be a reliable indicator of the overall health of the body’s circulatory system and the brain.
January 19, 2022
According to researchers, gaining a good understanding of what Musashi proteins do and how to manipulate their function could lead to the development of a universal therapy for blinding diseases.
January 18, 2022
ASCENT, REGENXBIO’s Phase III clinical trial conducted in partnership with AbbVie, is expected to enroll patients in the United States and Canada, with pivotal trials expected to support BLA submission for RGX-314 in 2024.